Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins

Journal of Clinical Oncology

Volumn 32, Issue 8, 2014, Pages 798-808

  Bollard, Catherine M ^a,b   Gottschalk, Stephen ^a,b   Torrano, Vicky ^a,b   Diouf, Oumar ^a,b   Ku, Stephanie ^a,b   Hazrat, Yasmin ^a,b   Carrum, George ^a,b   Ramos, Carlos ^a,b   Fayad, Luis ^c   Shpall, Elizabeth J ^c   Pro, Barbara ^c   Liu, Hao ^a,b   Wu, Meng Fen ^a,b   Lee, Daniel ^b,d   Sheehan, Andrea M ^a,b   Zu, Youli ^b,d   Gee, Adrian P ^a,b   Brenner, Malcolm K ^a,b   Heslop, Helen E ^a,b   Rooney, Cliona M ^a,b  

^a TEXAS CHILDREN S HOSPITAL   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; LATENT MEMBRANE PROTEIN 1; LATENT MEMBRANE PROTEIN 2; TUMOR ANTIGEN; EBV ASSOCIATED MEMBRANE ANTIGEN, EPSTEIN BARR VIRUS; EBV-ASSOCIATED MEMBRANE ANTIGEN, EPSTEIN-BARR VIRUS; MATRIX PROTEIN;

ADOLESCENT; ADOPTIVE TRANSFER; ADULT; AGED; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; AUTOTRANSPLANTATION; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CELL EXPANSION; CHEMORADIOTHERAPY; CHILD; CLINICAL ARTICLE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DNA MODIFICATION; EPSTEIN BARR VIRUS; FEMALE; HEART INFARCTION; HIGH RISK PATIENT; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; LYMPHOBLASTOID CELL LINE; MALE; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; SCHOOL CHILD; SECOND CANCER; TARGET CELL DESTRUCTION; TREATMENT RESPONSE; VIRAL GENE DELIVERY SYSTEM; VIRUS CELL TRANSFORMATION; YOUNG ADULT; ADENOVIRUS; ADOPTIVE IMMUNOTHERAPY; CELL LINE; CELL PROLIFERATION; CLINICAL TRIAL; DISEASE FREE SURVIVAL; GENE THERAPY; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; IMMUNOLOGY; KAPLAN MEIER METHOD; LYMPHOMA; METHODOLOGY; MORTALITY; PATHOLOGY; RECURRENT DISEASE; REMISSION; RISK FACTOR; TIME; TRANSPLANTATION; TREATMENT OUTCOME; UNITED STATES; VIROLOGY;

ADENOVIRIDAE; ADOLESCENT; ADULT; AGED; CELL LINE; CELL PROLIFERATION; CHILD; DISEASE-FREE SURVIVAL; FEMALE; GENETIC THERAPY; GENETIC VECTORS; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOTHERAPY, ADOPTIVE; KAPLAN-MEIER ESTIMATE; LYMPHOMA; MALE; MIDDLE AGED; RECURRENCE; REMISSION INDUCTION; RISK FACTORS; T-LYMPHOCYTES, CYTOTOXIC; TEXAS; TIME FACTORS; TRANSDUCTION, GENETIC; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; VIRAL MATRIX PROTEINS; YOUNG ADULT;

EID: 84898647949     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.51.5304     Document Type: Article

References (49)

1. Riddell SR, Watanabe KS, Goodrich JM, et al: Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 257:238-241, 1992
2. Peggs KS, Verfuerth S, Chow C, et al: Adoptive cellular therapy for cytomegalovirus following allogeneic stem cell transplantation: Toxicity and efficacy. Blood 104, 2005 (abstr 191)
3. Heslop HE, Brenner MK, Rooney CM: Donor T cells to treat EBV-associated lymphoma. N Engl J Med 331:679-680, 1994 (Pubitemid 24276876)
4. Leen AM, Myers GD, Sili U, et al: Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med 12:1160-1166, 2006 (Pubitemid 44527351)
5. Doubrovina E, Oflaz-Sozmen B, Prockop SE, et al: Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. Blood 119:2644-2656, 2012
6. Heslop HE, Slobod KS, Pule MA, et al: Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 115:925-935, 2010
7. Küppers R, Engert A, Hansmann ML: Hodgkin lymphoma. J Clin Invest 122:3439-3447, 2012
8. Grogg KL, Miller RF, Dogan A: HIV infection and lymphoma. J Clin Pathol 60:1365-1372, 2007 (Pubitemid 350247252)
9. Fox CP, Haigh TA, Taylor GS, et al: A novel latent membrane 2 transcript expressed in Epstein- Barr virus-positive NK- and T-cell lymphoproliferative disease encodes a target for cellular immunotherapy. Blood 116:3695-3704, 2010
10. Young LS, Rickinson AB: Epstein-Barr virus: 40 years on. Nat Rev Cancer 4:757-768, 2004 (Pubitemid 39331148)
11. Tierney RJ, Steven N, Young LS, et al: Epstein-Barr virus latency in blood mononuclear cells: Analysis of viral gene transcription during primary infection and in the carrier state. J Virol 68:7374-7385, 1994 (Pubitemid 24328793)
12. Roskrow MA, Rooney CM, Heslop HE, et al: Administration of neomycin resistance gene marked EBV specific cytotoxic T-lymphocytes to patients with relapsed EBV-positive Hodgkin disease. Hum Gene Ther 9:1237-1250, 1998 (Pubitemid 28269011)
13. Bollard CM, Aguilar L, Straathof KC, et al: Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease. J Exp Med 200:1623-1633, 2004 (Pubitemid 40094186)
14. Bollard CM, Straathof KC, Huls MH, et al: The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease. J Immunother 27:317-327, 2004 (Pubitemid 38833328)
15. Chia WK, Wang WW, Teo M, et al: A phase II study evaluating the safety and efficacy of an adenovirus-DeltaLMP1-LMP2 transduced dendritic cell vaccine in patients with advanced metastatic nasopharyngeal carcinoma. Ann Oncol 23:997-1005, 2012
16. Gottschalk S, Ng CY, Perez M, et al: An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs. Blood 97:835-843, 2001 (Pubitemid 32154261)
17. Bollard CM, Gottschalk S, Leen AM, et al: Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood 110:2838-2845, 2007 (Pubitemid 350006936)
18. Cheson BD, Pfistner B, Juweid ME, et al: Revised response criteria for malignant lymphoma. J Clin Oncol 25:579-586, 2007 (Pubitemid 350002966)
19. Cheson BD: New response criteria for lymphomas in clinical trials. Ann Oncol 19:iv35-iv38, 2008 (suppl 4)
20. Bollard CM, Gottschalk S, Helen Huls M, et al: Good manufacturing practice-grade cytotoxic T lymphocytes specific for latent membrane proteins (LMP)-1 and LMP2 for patients with Epstein-Barr virus-associated lymphoma. Cytotherapy 13:518-522, 2011
21. Gottschalk S, Edwards OL, Sili U, et al: Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies. Blood 101:1905-1912, 2003 (Pubitemid 36237592)
22. Sallusto F, Geginat J, Lanzavecchia A: Central memory and effector memory T cell subsets: Function, generation, and maintenance. Annu Rev Immunol 22:745-763, 2004 (Pubitemid 38680440)
23. Lanzavecchia A, Sallusto F: Progressive differentiation and selection of the fittest in the immune response. Nat Rev Immunol 2:982-987, 2002 (Pubitemid 37323221)
24. Rooney CM, Roskrow MA, Suzuki N, et al: Treatment of relapsed Hodgkin's disease using EBV-specific cytotoxic T cells. Ann Oncol 9:S129-S132, 1998 (suppl 5)
25. Meij P, Leen A, Rickinson AB, et al: Identification and prevalence of CD8(+) T-cell responses directed against Epstein-Barr virus-encoded latent membrane protein 1 and latent membrane protein 2. Int J Cancer 99:93-99, 2002 (Pubitemid 34273204)
26. Straathof KC, Leen AM, Buza EL, et al: Characterization of latent membrane protein 2 specificity in CTL lines from patients with EBV-positive nasopharyngeal carcinoma and lymphoma. J Immunol 175:4137-4147, 2005 (Pubitemid 41292078)
27. Miller G, Lipman M: Release of infectious Epstein-Barr virus by transformed marmoset leukocytes. Proc Natl Acad Sci U S A 70:190-194, 1973
28. Kern F, Faulhaber N, Frömmel C, et al: Analysis of CD8 T cell reactivity to cytomegalovirus using protein- spanning pools of overlapping pentadecapeptides. Eur J Immunol 30:1676-1682, 2000 (Pubitemid 30342810)
29. Chang ST, Ghosh D, Kirschner DE, et al: Peptide length-based prediction of peptide-MHC class II binding. Bioinformatics 22:2761-2767, 2006 (Pubitemid 44742396)
30. Gray RJ: A class of K-sample tests for comparing the culmulative incidence of a competing risk. Ann Stat 16:1141-1154, 1988
31. Reichert JM, Rosensweig CJ, Faden LB, et al: Monoclonal antibody successes in the clinic. Nat Biotechnol 23:1073-1078, 2005 (Pubitemid 41486385)
32. Gattinoni L, Powell DJ Jr, Rosenberg SA, et al: Adoptive immunotherapy for cancer: Building on success. Nat Rev Immunol 6:383-393, 2006
33. Kalos M, Levine BL, Porter DL, et al: T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 3:95ra73, 2011
34. Younes A, Bartlett NL, Leonard JP, et al: Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 363:1812-1821, 2010
35. Savoldo B, Ramos CA, Liu E, et al: CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest 121:1822-1826, 2011
36. Brentjens RJ, Davila ML, Riviere I, et al: CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 5:177ra38, 2013
37. Kochenderfer JN, Dudley ME, Feldman SA, et al: B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119:2709-2720, 2012
38. Icheva V, Kayser S, Wolff D, et al: Adoptive transfer of EBNA1-specific T cells as a treatment of Epstein-Barr virus reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation. J Clin Oncol 31:39-48, 2013
39. Straathof KC, Bollard CM, Popat U, et al: Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood 105:1898-1904, 2005 (Pubitemid 40731770)
40. Muranski P, Boni A, Wrzesinski C, et al: Increased intensity lymphodepletion and adoptive immunotherapy: How far can we go? Nat Clin Pract Oncol 3:668-681, 2006 (Pubitemid 44843125)
41. Morgan RA, Yang JC, Kitano M, et al: Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 18: 843-851, 2010
42. Grupp SA, Kalos M, Barrett D, et al: Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 368:1509-1518, 2013
43. Berger C, Jensen MC, Lansdorp PM, et al: Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest 118:294-305, 2008
44. Disis ML, Gooley TA, Rinn K, et al: Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol 20:2624-2632, 2002 (Pubitemid 34575634)
45. Butterfield LH, Ribas A, Dissette VB, et al: Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin Cancer Res 9:998-1008, 2003 (Pubitemid 36323703)
46. Wierecky J, Müller MR, Wirths S, et al: Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res 66:5910-5918, 2006 (Pubitemid 43927146)
47. Hunder NN, Wallen H, Cao J, et al: Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 358:2698-2703, 2008 (Pubitemid 351860862)
48. Cruz CR, Gerdemann U, Leen AM, et al: Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGEA4. Clin Cancer Res 17:7058-7066, 2011
49. Craddock C: Epigenetic manipulation of the immune response: A novel treatment strategy in hematologic malignancies. Cytotherapy 13:516-517, 2011